Zhengye Biotechnology Holding Limited (ZYBT)
| Market Cap | 45.59M -78.2% |
| Revenue (ttm) | 21.46M -19.0% |
| Net Income | -2.70M |
| EPS | -0.06 |
| Shares Out | 47.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,774 |
| Open | 1.0900 |
| Previous Close | 1.0100 |
| Day's Range | 0.9200 - 1.0900 |
| 52-Week Range | 0.7201 - 14.3000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 12, 2025 |
About ZYBT
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for household animals. In addition, it exports its products to Vietnam, Pakistan, and Egypt. The company serves direct-end customers, including livestock farmers a... [Read more]
Financial Performance
In 2024, ZYBT's revenue was 186.36 million, a decrease of -11.95% compared to the previous year's 211.65 million. Earnings were 11.31 million, a decrease of -64.04%.
Financial numbers in CNY Financial StatementsNews
Zhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to Shareholders
Jilin, China, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, developm...
Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results
JILIN, China , July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development,...
Zhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-F
Jilin, China, May 23, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, developme...
Zhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment Option
Jilin, China, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, developm...
U.S. IPO Weekly Recap: Flowco Launches First Major IPO Of 2025 As Smithfield, Others Join The Pipeline
Three very small Asian issuers and one blank check company listed in the US this past week, though the biggest headlines came from a sizable launch and notable new filings. Energy equipment and servic...
Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering
Jilin, China, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, developm...
Zhengye Biotechnology Holding Limited Announces Pricing of Initial Public Offering
Jilin, China, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufactur...
Zhengye Biotechnology's Growth Slows As It Seeks U.S. IPO
Zhengye Biotechnology Holding Limited has filed for a $20 million IPO to raise capital for its acquisition program and new development capabilities. The company's revenue has declined, but it still ma...